CLINICAL TRIALS PROFILE FOR CIBINQO
✉ Email this page to a colleague
All Clinical Trials for CIBINQO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05602207 ↗ | Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab | Not yet recruiting | Innovaderm Research Inc. | Phase 4 | 2022-11-01 | This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis. |
| NCT05743244 ↗ | Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) | Not yet recruiting | Pfizer | Phase 2 | 2023-05-30 | A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis. |
| NCT05743244 ↗ | Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | 2023-05-30 | A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CIBINQO
Condition Name
Clinical Trial Locations for CIBINQO
Trials by Country
Clinical Trial Progress for CIBINQO
Clinical Trial Phase
Clinical Trial Sponsors for CIBINQO
Sponsor Name
